Introduction {#S0001}
============

Pain conditions such as fibromyalgia and neuropathic pain cause substantial suffering,[@CIT0001] disability,[@CIT0002] and great societal costs.[@CIT0003] In addition, they are difficult to treat[@CIT0004],[@CIT0005] and sometimes difficult to diagnose.[@CIT0006]--[@CIT0008] Progress has been made in clinical classification and diagnostic criteria for neuropathic pain [@CIT0009],[@CIT0010] and fibromyalgia,[@CIT0011],[@CIT0012] but there is a need for better understanding of the pathophysiology and for more effective treatments.[@CIT0013]--[@CIT0017] Currently, there are no biological tests on which to base pain diagnoses, treatment choices or to understand the pathophysiology of the individual pain patient. Such markers that reflect the pathophysiology of individual pain patients would be important tools for pain clinicians, scientists, and pharmaceutical companies to aid in diagnosis, treatment selection, and to guide and monitor the development of new treatments. Although cerebrospinal fluid (CSF) collection is an invasive procedure, CSF is in direct contact with the brain and spinal cord and changes in CSF protein levels may reflect pathological processes in the central nervous system.[@CIT0018]

Neuropathic pain is often described as a particularly unpleasant form of pain[@CIT0019] with shooting, shock-like, aching, cramping, crushing, smarting, and burning features.[@CIT0020] Neuropathic pain is caused by lesion or disease of the somatosensory nervous system [@CIT0021] and affects 1--10% of the general population.[@CIT0022]^--^[@CIT0029] Previous investigations of CSF from neuropathic pain patients have typically analyzed one or a few interesting markers (mainly proteins) in small sample cohorts. Several studies have found differences in the levels of one or more proteins including inflammatory markers between neuropathic pain patients and controls[@CIT0030]^--^[@CIT0035] while other studies showed no significant differences.[@CIT0036],[@CIT0037]

Fibromyalgia affects around 2% of the population and is characterized by widespread pain and generalized hyperalgesia for mechanical pressure.[@CIT0038] Fibromyalgia patients often suffer from psychological distress, sleep and memory disturbances, and fatigue.[@CIT0038] There are many theories behind pathophysiology of FM, but the etiology is still uncertain. The current view is that the clinical presentation of fibromyalgia depends on central phenomena rather than peripheral dysfunction and substantial evidence exists for abnormalities in sensory signaling, including reduction of descending control and changes in key neurotransmitters associated with central sensitization.[@CIT0010] However, altered levels of cytokines, anti-inflammatory lipids, and prominent alterations both in muscle tissue and circulating proteins have been reported[@CIT0039]^--^[@CIT0044] as well as small nerve fiber impairment in FM.[@CIT0045] A wide range of proteins including inflammatory markers were found altered in the CSF of fibromyalgia patients.[@CIT0046]^--^[@CIT0053]

Biomarker profiles that can be used to characterize similarities and differences between chronic pain conditions would be valuable for understanding the pathophysiological mechanisms and give new leads for treatment development. In a recent mass spectrometry (MS) investigation of CSF samples, we demonstrated altered levels of several proteins associated with satisfactory spinal cord stimulation (SCS) treatment.[@CIT0054] Here, we applied the antibody suspension bead array technology that offers a flexible platform for parallel protein detection using only 15 µL of crude biological sample. It has previously been used to study CSF and plasma within other neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease.[@CIT0055]^--^[@CIT0057] In the present study, we identified CSF proteins associated with pain pathophysiology by comparing patients with neuropathic pain and fibromyalgia to CSF from controls without chronic pain.

Methods {#S0002}
=======

Subjects {#S0002-S2001}
--------

In this study, we analyzed a total of 199 CSF samples from neuropathic pain patients, fibromyalgia patients, and two types of controls ([Table 1](#T0001){ref-type="table"}). The first set of neuropathic pain patients (denoted NP1) included 14 individuals that were recruited from Uppsala University Hospital (mean age 57 (47--68), four males). They suffered from long-lasting neuropathic pain (median 10 years, range 3--23 years) and had permanently implanted spinal cord stimulation (SCS) since more than 3 months (median 3 years, range 1--10 years) with self-reported good pain relief. For these patients, samples were collected both when the stimulation was turned on and off.[@CIT0054]Table 1Patient and experimental overviewPatient groupNN femaleAge range (mean; median)Collection site**Stage 1**Neuropathic pain (NP1)141146--68 (56; 55)Uppsala, SwedenMinor urology surgery (C1)95421--81 (60; 65)Cluj, Romania**Stage 2**Neuropathic pain (NP2)11639--65 (55; 57)Linköping, SwedenHealthy controls (C2)11644--57 (52; 54)Linköping, SwedenMinor urology surgery (C3)28921--89 (51; 55)Cluj, RomaniaFibromyalgia (FM)404025--61 (47; 48)Oslo, Norway**Total**19976 (38%)[^1]

The second set of patients (denoted NP2) were 11 adults suffering from chronic (≥6 months) neuropathic pain due to trauma or surgery. These individuals participated in a clinical trial of intrathecal bolus injections of the analgesic ziconotide (ClinicalTrials.gov identifier NCT01373983), the mean age was 55 years (range 39--65) and six of the individuals were females. All samples were collected prior treatment at Linköping University Hospital in Sweden.

The fibromyalgia (FM) patients included in the study were 40 females (ages 20--60) suffering from FM as defined by the 1990 criteria of the American College of Rheumatology (ACR). Patient recruitment and sampling were performed at the privately operated Red Cross Hospital in Olso, Norway.

To find disease-associated proteins, the samples from the patients were compared to samples from two sets of controls. The largest control group consisted of 123 individuals undergoing spinal anesthesia for minor urological surgery at Cluj Hospital, Romania (C1 and C3, see Study design). Samples were collected according to the same protocol as in Uppsala, Sweden and although comparable in age, these individuals were mostly males. The other control cohort (C2) consisted of healthy volunteers matched to the NP2 patients and was collected simultaneously as the patients in Linköping, Sweden.

The sample collection procedures of all samples, from patient recruitment via lumbar puncture to aliquoting and storage, are detailed in [[Supplementary methods](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}.

Study design {#S0002-S2002}
------------

The experiments in this study were performed in two stages. The first stage of analysis included the NP1 patients from Uppsala, Sweden (n=14) and a subset of the Romanian controls (denoted C1, n=95). In the second stage, we analyzed the independent cohort of neuropathic pain CSF samples (NP2, n=11) and the samples from fibromyalgia patients (FM, n=40). These were compared to control samples from the healthy volunteers (C2, n=11) and the 28 additional controls from the Romanian cohort (denoted C3).

Creating the bead array {#S0002-S2003}
-----------------------

A bead microarray was customized and created using 100 antibodies from the Human Protein Atlas project ([[www.proteinatlas.org](http://www.proteinatlas.org)]{.ul}). These antibodies targeted 55 unique proteins that were selected based on an earlier mass spectrometry investigation of protein levels associated with satisfactory SCS treatment,[@CIT0054] see [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}. Immobilization of antibodies to beads was performed as previously described[@CIT0058] with one specific antibody assigned to a certain bead identity.

CSF analysis {#S0002-S2004}
------------

CSF samples were processed and analyzed through a direct labeling approach as previously reported.[@CIT0055] In short, CSF samples were diluted 1/2 in a protein-containing buffer (37.5 mg/mL bovine serum albumin (Sigma-Aldrich) in PBS with addition of 15 mg/mL rIgG (Bethyl Laboratories Inc., Montgomery, Texas, USA)) and a labeling solution with 10x molar excess of biotin (NHS-PEG4-Biotin, Thermo Scientific) over total protein amount, to a final volume of 30 µL. The reaction was terminated by addition of 250x Tris-HCl over biotin amount. Before applying samples to the bead array, they were further diluted one-eighth in assay buffer (PVXCas) to an end volume of 50 µL then heat treated at 56°C for 30 mins in a water bath. Following cooling to ambient temperature for 15 mins, 45 µL of sample was combined with 5 µL of the bead array solution and incubation was performed overnight. After washing off unbound proteins with 3×100 µL PBST (0.05% Tween-20), the interacting proteins were cross-linked during 10 mins using paraformaldehyde (0.4% in PBS). A second wash was followed by addition of detection reagent (streptavidin-conjugated R-phycoerythrin, Invitrogen, 1:750 diluted in PBST) and incubation was performed for 20 mins. Finally, the interacting proteins were analyzed using a FlexMap3D instrument (Luminex Corp., Austin, Texas, USA) and the relative abundance reported as median fluorescent intensities per sample and bead identity.

Verification of protein identities by immunocapture mass spectrometry (IC-MS) {#S0002-S2005}
-----------------------------------------------------------------------------

Assessment of antibody selectivity was performed by IC-MS as previously described.[@CIT0057] Briefly, antibodies coupled to magnetic beads were incubated with CSF from pooled human donors (Lee Biosolutions, Maryland Heights, Missouri, USA) diluted in assay buffer 1:10. After incubation, beads were washed and proteins captured were reduced, alkylated, and digested using trypsin and lysC (Promega, Madison, Wisconsin, USA). Peptides were re-suspended in buffer A (3% acetonitrile (ACN), 0.1% formic acid (FA) and separated on the Ultimate 3000 Rapid Separation Liquid Chromatography (RSLC) nanosystem (Dionex, Sunnyvale, California, USA). The analytical column was a 50 cm × 75 μm ID Easy spray (PepMap RSLC C18, Thermo Fisher). A linear gradient of Buffer B (90% ACN, 5% DMSO, 0.1% FA) was run in 50 mins at 250 nL/min (from 3% to 43%). MS analysis was performed using a Q-Exactive HF (Thermo Fisher) operated in a data-dependent mode with higher energy collision dissociation (HCD) on the top five most abundant ions. Full MS scan (300--1600 m/z) was performed at a resolution of 60,000. Database searching of raw data was performed on MaxQuant. Search parameters were set as in [@CIT0057] allowing for match between runs and label-free quantification using the MaxLFQ algorithm integrated into MaxQuant.[@CIT0059] Proteins identified in each IC-MS were compared with IC-MS performed for unrelated antibodies. Z-scores were calculated to rank the proteins enriched by each antibody and plotted against LFQ intensities.

Statistical analysis {#S0002-S2006}
--------------------

The intensities obtained from the antibody suspension bead array analysis were subjected to statistical analysis and visualization using R Studio (version 1.2.1335).[@CIT0060] Comparisons of protein levels were made within the same experimental stage only, to avoid any contribution to the results caused by inter-plate variation. For a general data overview, a principal component analysis (PCA, R package stats) of all groups was performed to assess general data quality and to remove potential outliers from further data analysis.

Multivariate data analysis was performed by projection (MVDA) using SIMCA-P+, version 13.0 (Umetrics AB, Umeå, Sweden).[@CIT0032],[@CIT0061] Data were log-transformed when needed (using the transform function in SIMCA-P+) and scaling was done according to the unit variance method. Outlier detection for the multivariate model was performed using Hotelling's T^2^ (T^2^ Critical 99%) for strong outliers and by distance to model in X-space (DModX) for serious moderate outliers. Then, orthogonal partial least squares -- discriminant analysis (OPLS-DA) was used to identify class-discriminating proteins. The significance of OPLS-DA models was assessed by analysis of variance of cross-validated predictive residuals (CV-ANOVA), and the relative contribution of the proteins for group discrimination was determined by the predictive loadings and by the corresponding loadings scaled as a correlation coefficient, denoted p(corr), between the model and original data. An absolute *p*(corr)≥0.5 was considered significant.[@CIT0062]

For univariate analysis, statistical significance of group differences was evaluated by the Wilcoxon rank sum test (R package *stats*) and *p*-values below 0.05 after multiple testing correction (FDR) were regarded as significant. To select proteins of interest, the assays of the first stage were repeated twice and proteins of interest selected based on concordant significant differences.

Results {#S0003}
=======

In this study, we have performed CSF profiling using an affinity proteomics approach in order to investigate 55 proteins with potential relevance for pain pathophysiology and pain treatment. Our sample set consisted of in total 199 CSF samples from 65 patients and 134 controls ([Table 1](#T0001){ref-type="table"}). In the first experimental stage, we analyzed CSF from 14 patients with neuropathic pain on and off SCS treatment (NP1) and 95 controls without pain pathology that underwent minor urological surgery (C1). To validate the results, an independent set of CSF samples from patients with neuropathic pain (NP2) were analyzed together with matched controls (C2) as well as additional control subjects from the Romanian site (C3).

Multivariate protein signatures {#S0003-S2001}
-------------------------------

To explore disease-associations in a multivariate manner, we performed OPLS-DA analysis of the complete datasets generated in both stage I and stage II. In the first stage, 10 outliers (eight controls and two patients) were removed after initial PCA, rendering a final PCA model with four latent variables, R^2^=0.60, and Q^2^=0.52. Then, an OPLS-DA model was computed to discriminate between NP1 and C1 (referred to as model 1, four latent variables, R^2^=0.85, Q^2^=0.67, and *p*\<0.001) and the proteins with significant contribution to the model (\|*p*(corr)\| ≥0.5) were apolipoprotein C-I (APOC1), keratin 1 (KRT1), apolipoprotein A1 (APOA1) and neurexin-1 (NRXN1) ([Figure 1](#F0001){ref-type="fig"} and [[Table S2A](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}). It was not possible to generate an OPLS-DA model comparing neuropathic pain patients to healthy controls from the same center (NP2 vs C2), indicating subtle differences in protein levels between groups. Nevertheless, models were calculated for NP2 compared to C3 (referred to as model 2, five latent variables, R^2^=0.98, Q^2^=0.86, and *p*-value\<0.001) with 14 proteins contributing significantly ([[Table S2B](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}). When comparing the results from model 1 and 2, the protein with significant contribution in both models was APOA1. Although not significant, APOC1, KRT1, and NRXN1 were just under the significance threshold with \|*p*(corr)\| of 0.38, 0.44, and 0.49, respectively.Figure 1Score plot of multivariate model discriminating neuropathic pain patients and controls. Visualization of the first three latent variables from OPLS-DA model 1, neuropathic pain patients (NP1, green dots) vs controls (C1, blue dots). The t\[1\] axis represents interclass variation, whereas the two other two axes (to\[1\] and to\[2\]) represent intra-class variation.

For fibromyalgia, one patient sample was identified as an outlier and removed. Two OPLS-DA models were then computed, one comparing the fibromyalgia patients to C2 (referred to as model 3 with five latent variables, R^2^=0.95, Q^2^=0.75, *p*-value \<0.001 and C3 (referred to as model 4 with five latent variables, R^2^=0.94, Q^2^=0.80, *p*-value\<0.001). Model 3 were based on seven significantly contributing proteins ([[Table S2C](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}), but in model 4 only autotaxin (or ectonucleotide pyrophosphatase/phosphodiesterase family member 2, ENPP2) contributed significantly.

Increased levels of APOC1 in neuropathic pain patients {#S0003-S2002}
------------------------------------------------------

In the first analysis stage, we observed no significant differences between samples collected from patients on and off SCS treatment using univariate statistics (data not shown). In the comparison between patients and controls, the two proteins APOC1 and secretogranin-1 (CHGB also referred to as SCG1) were found at significantly higher levels in the CSF of neuropathic pain patients off SCS treatment (NP1) compared to controls (C1). In addition, NRX1, APOA1, dickkopf-related protein 3 (DKK3), superoxide dismutase 1 (SOD1), complement factor H (CFH), prostaglandin-H2 D-isomerase (PTGDS), complement component C7 (C7), and hemopexin (HPX) were observed at lower levels in the patients (*p*-value\<0.05, [Table 2](#T0002){ref-type="table"}).Table 2Proteins with significantly altered levels in neuropathic pain patientsGeneProteinAntibodyp-valueAdj. p-valueFold change*APOC1*Apolipoprotein-C1HPA0515180.000010.00011.1*CHGB*Secretogranin 1HPA0126020.00030.010.1*NRXN1*Neurexin-1HPA0599630.000010.0001-0.3*APOA1*Apolipoprotein-A1HPA0467150.000010.0001-0.6*DKK3*Dickkopf related protein 3HPA0111640.00010.001-0.3*SOD1*Superoxide dismutase 1HPA0014010.00010.001-0.8*CFH*complement factor HHPA0533260.00070.01-0.2*PTGDS*ProstaglandinHPA0049380.0010.01-0.2*C7*complement component C7HPA0674500.0020.01-0.3*HPX*HemopexinHPA0688470.0040.01-0.3[^2]

In the second stage analysis, none of the 10 proteins showed significant differences between the NP2 patients and both control groups although APOC1 (detected by antibody HPA051518) showed near significant and concordant trends with higher CSF levels in patients compared to both C2 and C3 ([Figure 2](#F0002){ref-type="fig"}, uncorrected *p*-values 0.3 and 0.05, respectively). When comparing the pain patients and controls collected at the same site (NP2 and C2), the protein osteoglycin (OGN) was significantly altered before correction for multiple testing (uncorrected *p*-value 0.006). However, this protein was found at similar levels in patients and controls in the comparison of NP1 and C1 (*p*-value 0.8).Figure 2CSF levels of APOC1 in (**A**) neuropathic pain patients (NP1) compared to controls (C1) in the first stage and (**B**) for neuropathic pain patients (NP2) and fibromyalgia (FM) compared to controls (C2 and C3) in the second analysis stage. Significant differences are indicated with *p*-values. MFI -- median fluorescence intensity.

Increased levels of ENPP2 in fibromyalgia patients {#S0003-S2003}
--------------------------------------------------

To explore proteins with potential association to fibromyalgia pathology, profiles of fibromyalgia patients (FM) were compared to the two separate control groups analyzed in the second stage (C2 and C3). Summarizing the results, APOC1 and ENPP2 (antibody HPA053652) were the two proteins with concordant differences in patients compared to the control groups, both observed with higher levels in the patients ([Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}). For APOC1, the difference was statistically significant in the comparison with C3 (*p*-value 0.005) while comparison to C2 was not significant after *p*-value correction (uncorrected *p*-value 0.03). The levels of ENPP2, on the other hand, were significantly higher in patients compared to both control groups (0.0001 for FM vs C2 and 0.000003 for FM vs C3). Levels of ENPP2 were also increased in fibromyalgia patients compared to those with neuropathic pain (NP2, *p*-value 0.0000003)Figure 3CSF levels of ENPP2 in (**A**) neuropathic pain patients (NP1) compared to controls (C1) in the first stage and (**B**) for neuropathic pain patients (NP2) and fibromyalgia (FM) compared to controls (C2 and C3) in the second analysis stage. Significant differences are indicated with p-values. MFI -- median fluorescence intensity.

Antibody validation by IC-MS {#S0003-S2004}
----------------------------

We applied immunocapture mass spectrometry (IC-MS) in order to verify the selectivity of the antibodies targeting APOC1 (HPA051518) and ENPP2 (HPA053652). Both antibodies captured and enriched their intended target when incubated with CSF from healthy donors ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}). APOC1 was the protein mostly enriched by HPA051518 (z-score 2.59, LFQ intensity 1,765,450,000) but also APOA1 and apolipoprotein E (APOE) were detected. ENPP2 was identified as captured by the HPA053652 antibody (z-score 2.60, LFQ Intensity: 54,462,500) together with the additional proteins Collagen alpha-3(VI) chain (COL6A3), Myosin heavy chain 7 (MYH7), and prothrombin (F2) ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}). See [[Table S3](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul} for all Z-scores and LFQ intensities.

Discussion {#S0004}
==========

In this study, we performed protein profiling of human CSF samples. We measured levels of 55 proteins previously identified to have a potential role in pain treatment. Our study material consisted of samples from 199 individuals of which 25 were patients with neuropathic pain, 40 patients with fibromyalgia and 134 controls.

Increased levels of APOC1 in CSF of neuropathic pain patients {#S0004-S2001}
-------------------------------------------------------------

The analysis of the first neuropathic pain cohort and controls demonstrated that APOC1 levels were significantly increased in patients. We also found a non-significant increase of CSF APOC1 in the verification sample set as well as an increase of APOC1 in fibromyalgia patient samples compared to both control groups.

The source of alterations in APOC1 levels may be central or peripheral. Peripheral APOC1 is mainly synthesized in the liver, circulates in the blood bound to lipoprotein particles and is involved in cholesterol and lipid homeostasis.[@CIT0063] APOC1 deriving from the central nervous system is produced by astrocytes, microglia, and endothelial cells.[@CIT0064] Less is known about the role of apolipoproteins in the central nervous system (CNS).[@CIT0065] The blood-brain barrier (BBB) and the blood-spinal cord barrier (BSCB) limit the exchange of lipoprotein particles between the blood and the CNS, but HDL-like particles are able to cross. Thus, APOC1 CSF level alterations such as reported here may be caused by APOC1 having traversed CNS barriers in HDL-like particles as part of a normal cross-barrier communication or through "leakier" brain or spinal cord barriers induced by nerve injury.[@CIT0066],[@CIT0067] A recent study of rodents suggested that the lumbar spinal cord is the source of increased serum levels of apolipoproteins after nerve injury.[@CIT0068] This suggests that even local spinal cord increases of apolipoproteins can be reflected not only in CSF but also in the blood a long time after injury. This further suggests that apolipoprotein levels in serum or plasma could be suitable as markers of ongoing pain relevant processes in the spinal cord.

We have recently found signs of inflammation in the CSF of neuropathic pain patients [@CIT0069] as well as in the serum of patients with sciatic pain one year after disc hernia.[@CIT0070] APOC1 can modulate inflammatory processes[@CIT0071] and may play a role in chronic inflammation.[@CIT0072]--[@CIT0075] APOC1 enhances the toll-like receptor 4 (TLR4)-dependent inflammatory response[@CIT0075],[@CIT0076] that induce production of pro-inflammatory cytokines and reactive oxygen species,[@CIT0077],[@CIT0078] and is an important part of glial activation in rodent models of neuropathic pain.[@CIT0077],[@CIT0079]--[@CIT0082] Neuropathic pain-like behaviors can be reversed by intrathecal injection of TLR4 antagonists.[@CIT0083] TLR4 can be activated by endogenous ligands,[@CIT0084] cell products released upon injury[@CIT0085] and in neuropathic pain models, additional cofactors are required to enhance TLR4-dependent signaling.[@CIT0086] Since the BSCB is more permeable after nerve injury [@CIT0067] it may allow entry of several such ligands. Thus, we hypothesize that the high levels of APOC1 we find in neuropathic pain patient CSF in this study may contribute to increased TLR4 activity which can explain parts of the prolonged glial activation and signs of central neuroinflammation seen in neuropathic pain conditions.[@CIT0053] Interestingly, TLR4 antagonists, as well as small molecule modulators, are being investigated as drug candidates for pain treatment.[@CIT0087] but paradoxically, APOC1 has also been found to be immunosuppressive.[@CIT0088] These apparently contradicting results are not fully understood.

Another interpretation is that the increased levels of APOC1 observed reflect an ongoing CNS degeneration and regeneration in persistent neuropathic pain conditions. Apolipoproteins are known to contribute to nerve cell regeneration by local delivery of lipids and other unknown mechanisms.[@CIT0068] Lipid metabolism is central to CNS homeostasis, especially due to myelin which is required for optimal neuronal and network function. Several studies have shown that APOC1 and APOE are closely linked both genetically [@CIT0089],[@CIT0090] and functionally.[@CIT0091] Levels of other apolipoproteins have recently been shown to be altered in neuropathic and discogenic pain patient CSF compared to controls[@CIT0032],[@CIT0092] as well as after nerve injury in rat models.[@CIT0068],[@CIT0093] In the present investigation, APOE levels were not found to be significantly altered in fibromyalgia or neuropathic pain, although there are at least four previous studies linking APOE gene variants and APOE levels to risk of persistent pain.[@CIT0094]--[@CIT0097] To our knowledge, there are no previously published results directly linking APOC1 to persistent pain or its treatments.

Increased levels of ENPP2 in CSF of patients with fibromyalgia {#S0004-S2002}
--------------------------------------------------------------

The ENPP2 protein was found to be significantly increased in CSF from patients with fibromyalgia when compared to both groups of controls as well as patients with neuropathic pain. To our knowledge, a direct relation between ENPP2 and fibromyalgia has not been reported previously, but ENPP2 inhibitors have been patented for treatment of fibromyalgia.[@CIT0098] ENPP2 has also been demonstrated to increase in CSF from patients with chronic fatigue syndrome (CFS),[@CIT0099] a condition that shares characteristics with fibromyalgia. There are also reports of important pain modulating the activity of two of the main products of ENPP2.[@CIT0100]

ENPP2 is an enzyme with lysophospholipase D activity that catalyzes the formation of the lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine.[@CIT0101] A recent publication states that LPA signaling is the mechanism behind neuropathic pain and also refers to unpublished observations that LPA signaling appears to play a crucial role in fibromyalgia.[@CIT0102] Under normal conditions, LPA promotes healing after tissue trauma and negatively regulates ENPP2 transcription. In a high cytokine environment, LPA can induce ENPP2 expression to increase overall LPA concentrations in a positive feedback loop.[@CIT0103] LPA is an important pro-inflammatory mediator in the spinal cord. Neuroinflammation can cause neurodegeneration[@CIT0104] and it has been reported that blocking LPA can improve recovery after spinal cord injury as LPA has been shown to cause nerve demyelination.[@CIT0105],[@CIT0106] Distal demyelinating polyneuropathy has been reported in a subset of fibromyalgia patients[@CIT0107] and at least six studies have reported peripheral small fiber abnormalities in fibromyalgia patients.[@CIT0108]^--^[@CIT0113] Heterozygous mutant mice (ENPP2+/−) display a 50% decrease in ENPP2 activity, reduced LPA production and, interestingly, better recovery from neuropathic pain-like behaviors after injury.[@CIT0114]^--^[@CIT0116] Therefore, ENPP2 has been of interest as an upstream target of LPA and for the treatment of neuropathic pain.[@CIT0117] It is noteworthy that we observed no increase of ENPP2 in neuropathic pain patients; however, the present investigation does not contain any information of potential changes in ENPP2 activity levels or production of its metabolites.

ENPP2 has a functional domain[@CIT0118] which regulates oligodendrocyte process outgrowth and branching.[@CIT0119]^--^[@CIT0121] ENPP2 can also act on sphingosylphosphorylcholine to produce sphingosine-1-phosphate (S1P)[@CIT0122] which has been found to modulate spinal nociceptive processing[@CIT0123] and excitability of dorsal root ganglion sensory neurons.[@CIT0124],[@CIT0125] Concentrations of CSF S1P have also been reported as decreased in an animal model of acute and inflammatory pain.[@CIT0126] Neuronal S1P~1~ receptors play an important role in nociceptor regulation and S1P signaling is a suspected mediator of the onset of thermal hypersensitivity and hyperalgesia associated with inflammation.[@CIT0127] Central S1P has been shown to have anti-nociceptive effects, but there appear to be many points of regulation and the interactions are not fully understood as reviewed by others.[@CIT0128] An untargeted metabolomics investigation of a rodent neuropathic pain model suggests that altered levels of sphingolipids are part of the chronic pain pathophysiology.[@CIT0129]

A hypothesis that can be generated from our result is that the high levels of ENPP2 indicate elevated levels of LPA or S1P, mediators which were not measured in this study. If so, these inflammatory agents could damage or alter activity of components of the patient's nervous tissue and contribute to their pain and other symptoms. Because CFS patients were also reported to have high ENPP2 levels,[@CIT0099] another hypothesis is that ENPP2 levels somehow reflect the impaired sleep quality commonly described in both CFS and fibromyalgia. It could also be so that increased levels of ENPP2 are a secondary effect due to alterations in other factors regulating the clearance of proteins.[@CIT0130]

Target identification by IC-MS {#S0004-S2003}
------------------------------

IC-MS analysis was performed to evaluate the selectivity of antibodies targeting APOC1 and ENPP2 and in both cases, the intended targets were detected. The additional proteins present may represent competitors (off-target interactors) or proteins in a complex with the target and so co-immunoprecipitated with it. The alignment of the three sequences APOC1, APOA, APOE performed by CLUSTALO shows a low identity 1.52%. APOC1-APOA1: 7.72%. APOC1-APOE: 4.42% between APOC1 and the two apolipoproteins. This would poorly support an off-target binding while the hypothesis that APOC1 may be captured in a complex with APOA and APOE is partially supported by literature.[@CIT0131]--[@CIT0133]

Even though several other proteins appear to be enriched by the ENPP2 antibody with similar z-score values, only ENPP2 and PLG were exclusively identified in the IC-MS experiment performed using HPA053652. The low LFQ intensity associated with PLG and also to the other proteins indicate that they may represent contaminant proteins. As shown in other studies,[@CIT0134] several contaminant proteins are identified in immunoprecipitation experiments and only the screening of a higher number of negative control and replicates allows discrimination of co-immunoprecipitating proteins from background. In this experimental setting, results from only 16 different IC-MS experiments have been compared (data not shown).

In conclusion, the data of IC-MS are supportive for the validation of the two antibodies targeting APOC1 and ENPP2 used in the bead array screening, and further studies would be required to investigate if they are captured in a complex with other proteins.

Study limitations {#S0004-S2004}
-----------------

CSF more closely mirrors the microenvironment of the central nervous system than plasma. However, lumbar puncture involves a medical risk for study subjects and access to both patient and healthy control CSF material is limited.

We have analyzed samples from multiple clinical locations and countries (Sweden, Norway, and Romania). Pre-analytical parameters such as collection tube type, sample volume, time from collection to centrifugation, freezing cycles, and storage temperature can affect the detectable proteome[@CIT0135],[@CIT0136] as can geographical differences and population lifestyle. In order to reduce the contribution of these factors to variation, the same CSF sample collection and handling protocol were used in Sweden and Romania and the person performing the lumbar punctures for the control samples in Cluj, Romania was trained with the clinicians in Uppsala, Sweden. Despite this, we did observe differences in protein profiles between samples from the different clinics. Therefore, we included additional control groups, compared the control groups to each other and filtered out differences derived from sampling site. There was a difference in both centrifugation protocol and sample freezer storage time between the Norwegian sample set and the others of 15 years. Enroth et al, analyzed plasma samples with a difference of 26 years in sample storage time and reported that for 10% of the proteins, sample storage time could explain 5--35% of the observed variance in protein level.[@CIT0137] It is not clear if ENPP2 belongs to the group of proteins that are affected by sample storage time, or how storage time effects in CSF differ from that of plasma, as plasma contains 100--200 times more protein than CSF.

There was also a gender bias among the included subjects. The sample set from minor urology surgery patients naturally contains more males than females. All the fibromyalgia CSF samples were from female patients, yet they were compared to samples from mixed sex groups. Sex has not proven to influence CSF proteins in our previous investigations with the exception of the expected difference in prostate-specific antigen.[@CIT0138] Nevertheless, to address this potential bias we performed group comparison analysis with only female participants and the data generated in stage II. The results showed that the levels of ENPP2 were significantly higher also in patients compared to both the female neuropathic pain patients and the female controls ([[Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=215348.pdf)]{.ul}). As is typical in persistent pain, most patients in the study were on medications.[@CIT0002] Although interference cannot be ruled out, there are indications from other studies that drugs do not necessarily interfere with the protein profile in CSF[@CIT0050] or on glial activation in patients.[@CIT0139]

Conclusion {#S0005}
==========

We found increased levels of APOC1 in CSF of both patients with neuropathic pain and fibromyalgia while increased levels of ENPP2 were found only in the CSF of patients with fibromyalgia. Available literature supports the involvement of lipids in both neuropathic pain and fibromyalgia pathophysiology and supports further investigation of these proteins and their mediators to determine their potential role in human pain pathophysiology.
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[^1]: **Notes:** Summary of all sample sets included in this study. C1 and C3 control samples were from the same patient population but were divided into two groups for inclusion in both experimental stages.

[^2]: **Notes:** Proteins with altered CSF levels between patients and controls in stage 1 comparing NP1 to C1.
